摘要
目的：观察紫杉醇联合顺铂治疗中晚期非小细胞肺癌的近期疗效及毒副作用。方法：对34例中晚期非小细胞肺癌患者应用国产紫杉醇135 mg/m^2,d1静脉滴注;顺铂75 mg/m^2,d2-4静脉滴注,21天为1疗程,连用2个疗程。结果：34例均可评价疗效,总有效率（完全缓解＋部分缓解）为41.2%。鳞癌和腺癌、Ⅲ期和Ⅳ期患者总有效率差异均无统计学意义（P〉0.05）,而初治患者总有效率高于复治患者（P〈0.05）。毒副作用主要表现为骨髓抑制、脱发和关节肌肉疼痛,其他毒副作用较轻。结论：紫杉醇联合顺铂治疗中晚期非小细胞肺癌疗效较好,毒副作用可以耐受。
Objective ：To evaluate the effect and side-effect of combined chemotherapy with paclitaxel（PTX） plus cisplatin（DDP） in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods：Thirty-four patients with advanced NSCLC received PTX 135 mg/m^2 by intravenous infusion on d1 ,and DDP 75 mg/m^2 by intravenous infusion on d2-4. The treatment was repeated every 21 days, up to 2 cycles. Results：Thirty-four patients were evaluable for efficacy,with an overall rate of 41.2%. The response rate of squamous cell carcinoma was no significant difference to that of adenocarcinoma. And there was also no significant difference between the Ⅲ stage patients and the Ⅳ stage patients （P 〉 0.05）. But the response rate of primary treatment was significantly different to that of relapse treatment （P 〈 0.05 ）. The main toxicities were myelosuppression, nausea and vomiting, and other side effects were mild. Conclusions ：A high response rate can be obtained in advanced NSCLC by PTX plus DDP. PTX plus DDP combined therary is a promising antitumor protocol with tolerable toxicity.
出处
《蚌埠医学院学报》
CAS
2009年第8期682-684,共3页
Journal of Bengbu Medical College
关键词
肺肿瘤
肿瘤/药物疗法
癌
非小细胞肺
紫杉醇
顺铂
lung neoplasms
neoplasms/drug therapy
carcinoma, non-small cell lung
paclitaxel
cisplatin
